目的 探討阿帕替尼聯(lián)合卡培他濱治療胃癌患者的臨床療效及其對血清腫瘤標(biāo)志物水平的影響。方法 回顧性分析2016年11月—2020年11月中國科學(xué)院中關(guān)村醫(yī)院收治的80例胃癌患者，根據(jù)治療方法將患者分為對照組（41例）和觀察組（39例）。對照組患者口服卡培他濱片，1 000 mg/m²，2次/d，治療2周后停藥1周，21 d為1個周期。觀察組在對照組的基礎(chǔ)上口服甲磺酸阿帕替尼片，500 mg/次，1次/d，治療2周，21 d為1個周期?；颊咝杈S持用藥3個周期。觀察兩組患者的臨床療效，同時比較兩組治療前后的血清腫瘤標(biāo)志物［糖類抗原724（CA724）、糖類抗原19-9（CAl9-9）、糖類抗原125（CA125）、癌胚抗原（CEA）］、血清Th1/Th2細(xì)胞因子［γ干擾素（IFN-γ）、白細(xì)胞介素-2（IL-2）、白細(xì)胞介素-4（IL-4）、白細(xì)胞介素-10（IL-10）］水平。結(jié)果 治療后，觀察組總有效率為84.6%，顯著高于對照組的48.8%（P<0.05）。治療后，兩組CA724、CAl9-9、CA125和CEA水平均顯著降低（P<0.05）；治療后，觀察組血清腫瘤標(biāo)志物水平顯著低于對照組（P<0.05）。治療后，兩組IFN-γ、IL-2水平顯著升高，IL-4、IL-10水平顯著降低（P<0.05）；且觀察組血清Th1/Th2細(xì)胞因子水平顯著優(yōu)于對照組（P<0.05）。結(jié)論 阿帕替尼聯(lián)合卡培他濱治療胃癌具有明顯的治療效果，可以有效降低機體中的血清腫瘤標(biāo)志物水平，調(diào)節(jié)機體中的血清Th1/Th2細(xì)胞因子水平，同時沒有增加不良反應(yīng)，安全性高，值得推廣借鑒。

Objective To investigate the clinical efficacy of apatinib combined with capecitabine in treatment of gastric cancer patients and its effect on serum tumor markers. Methods Eighty patients with gastric cancer admitted to Zhongguancun Hospital of Chinese Academy of Sciences from November 2016 to November 2020 were retrospectively analyzed, and the patients were divided into control group (41 cases) and observation group (39 cases) according to treatment methods. Patients in the control group were po administered with Capecitabine Tablets, 1 000 mg/m², twice daily. After 2 weeks of treatment, the drug was stopped for 1 week, 21 days as a cycle. Patients in the observation group were po administered with Apatinib Mesylate Tablets on the basis of control group, 500 mg/time, once daily for 2 weeks, 21 d as a cycle. Patients were required to maintain medication for 3 cycles. After treatment, the clinical efficacy of two groups was observed. And the serum tumor markers (CA724, CAL9-9, CA125, CEA), serum Th1/Th2 cytokines (IFN-γ, IL-2, IL-4, IL-10) before and after treatment were compared between two groups. Results After treatment, the total effective rate of observation group was 84.6%, which was significantly higher than 48.8% of control group (P < 0.05). After treatment, the levels of CA724, CAL9-9, CA125, and CEA in two groups were significantly decreased (P < 0.05). After treatment, the level of serum tumor markers in observation group was significantly lower than that in control group (P < 0.05). After treatment, the levels of IFN-γ and IL-2 in two groups were significantly increased, while the levels of IL-4 and IL-10 were significantly decreased (P < 0.05). The serum Th1/Th2 cytokine level of observation group was significantly better than that of control group (P < 0.05). Conclusion Apatinib combined with capecitabine in treatment of gastric cancer has obvious therapeutic effect, can effectively reduce the level of serum tumor markers, regulate the level of serum Th1/Th2 cytokines, without increasing adverse reactions, high safety, worthy of promotion and reference.

R979.1